Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSatellos Bioscience Inc

Satellos Bioscience Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.56 CAD 0.01 ( 1.82%)
Last update at 2024-02-14T20:08:00Z
VOLUME
53750
Market Cap
54.70M

Momentum Score

…

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company's MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.56
Low
0.58
High
52 Week Price Range
0.26
Low
0.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.55
Dividend Yield
-
Revenue TTM
-0.05M
Revenue Per Share
-0.00
Gross Profit TTM
-0.07M
Debt / Equity
-
ROE
-52.88%
Net Debt
0.38M
ROCE
-248.73%
Diluted EPS TTM
-0.25

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -11.32M -15.51M -1.58M -
Net income -11.32M -15.51M -1.58M -
Selling general administrative 5.44M 2.60M 0.90M -
Gross profit - -0.12M -0.05M -
Reconciled depreciation 0.34M 0.17M 0.00M -
Ebit -8.38M -4.77M -1.57M -2.00M
Ebitda -10.98M -4.49M -1.47M -
Operating income -8.38M -4.66M -1.48M -
Interest expense 0.00M 0.99M 0.02M 0.00M
Tax provision 0.01M - - -
Interest income 0.02M 0.01M 0.00M -
Net interest income 0.02M -0.93M -0.01M -
Income tax expense 0.01M - - -
Total revenue 0.00M 0.00M 0.00M -
Total operating expenses 8.38M 4.66M 1.48M -
Cost of revenue - 0.12M 0.05M -
Total other income expense net -2.96M -9.92M -0.09M -
Net income from continuing ops -11.32M -15.51M -1.58M -
Net income applicable to common shares -11.32M -15.51M -1.58M -1.99M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6.20M 12.59M 1.13M -
Intangible assets 3.92M 7.14M - -
Other current assets 0.00M - - -
Total liab 2.83M 2.10M 1.31M -
Total stockholder equity 3.37M 10.48M -0.18M -
Other current liab - - 0.02M 0.03M
Common stock 30.21M 28.32M 4.36M 3.46M
Capital stock 30.21M 28.32M 4.36M -
Retained earnings -31.61M -20.29M -4.79M -3.21M
Cash 1.92M 4.87M 0.72M -
Total current liabilities 2.83M 2.10M 0.22M 0.66M
Net debt - - 0.38M -
Other stockholder equity 2.10M 1.22M - -
Property plant equipment 0.01M 0.01M 0.00M 0.00M
Total current assets 2.23M 5.44M 1.13M 1.07M
Long term investments 0.04M - - -
Net tangible assets -0.55M 3.35M -0.18M 0.41M
Net receivables 0.26M 0.53M 0.41M 0.66M
Long term debt - - 1.09M -
Accounts payable 1.47M 1.13M 0.13M 0.63M
Non current assets total 3.97M 7.14M 0.00M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.00M 1.74M 0.00M -
Change to liabilities 0.73M -0.39M -0.44M 0.48M
Total cashflows from investing activities -0.00M 1.74M 1.74M -0.00M
Net borrowings - 0.19M 1.09M 1.09M
Total cash from financing activities 2.77M 7.45M 1.98M 1.16M
Change to operating activities 0.26M -0.14M 0.29M -0.44M
Net income -11.32M -15.51M -1.58M -1.99M
Change in cash -2.95M 4.15M 0.32M -0.77M
Begin period cash flow 4.87M 0.72M 0.40M -
End period cash flow 1.92M 4.87M 0.72M 0.40M
Total cash from operating activities -5.71M -5.03M -1.66M -1.92M
Issuance of capital stock 2.00M 0.40M 0.89M -
Depreciation 0.34M 0.17M 0.00M 0.00M
Change to account receivables 0.00M 0.04M -0.03M -0.01M
Other cashflows from financing activities 0.78M 0.78M 0.78M 0.78M
Change to netincome 4.28M 10.79M 0.10M 0.04M
Capital expenditures 0.00M 0.01M 0.01M 0.00M
Change in working capital 0.99M -0.49M -0.18M -
Stock based compensation 1.44M 0.97M 0.09M -
Other non cash items - 9.84M 0.01M -
Free cash flow -5.72M -5.04M -1.66M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MSCL
Satellos Bioscience Inc		 0.01
1.82%		 0.56 - - 360.97 1.18 -0.57
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16

Profile*

Satellos Bioscience Inc

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company's MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

65 Front Street East, Toronto, ON, Canada, M5E 1B5

647 660 1780

https://satellos.com

Name Title Year Born
Mr. Francis Gleeson B.B.A. M.B.A Co-Founder, CEO, Pres & Director 1955
Dr. Michael A. Rudnicki Ph.D. Co-Founder & Chief Scientific Officer 1961
Mr. Warren Whitehead C.M.A., CPA Chief Financial Officer 1952
Mr. William Wasyl Jarosz Exec. Director 1956
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA Strategic Advisor 1960
Dr. Philip Lambert M.A., Ph.D. Chief Technology Officer 1968
Mr. J. Robert Hall CFA VP of Fin. & Admin. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…